据官方消息，由区块链基础设施自动化公司 Zeeve 提供支持的平行链部署工具 Perfuse 已获得 Web3 基金会 Decentralized Futures 资助，具体金额暂未披露 ...

SAN FRANCISCO, May 6, 2025 /PRNewswire/ -- Perfuse Therapeutics, Inc. ("Perfuse Therapeutics"), a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular ...

All patients were followed for 24 weeks after receiving a single dose. About Perfuse Therapeutics, Inc.

("Perfuse Therapeutics"), a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular diseases, today announced positive 24-week results from its completed ...

2025 /PRNewswire/ -- Perfuse Therapeutics, a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular diseases announced today the presentation of 24-week ...

SAN FRANCISCO, May 6, 2025 /PRNewswire/ -- Perfuse Therapeutics, Inc. ("Perfuse Therapeutics"), a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular ...

Perfuse Therapeutics has reported 24-week data from its first-in-human, multi-centre Phase I/IIa trial of the PER-001 intravitreal implant for individuals with glaucoma. The trial of PER-001 is ...